isopropyl-phenyl-phosphinic acid ethyl ester | 53716-14-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: isopropyl-phenyl-phosphinic acid ethyl ester
• 英文别名: O-ethyl P-phenyl-P-isopropylphosphinate；Isopropyl-phenyl-phosphinsaeure-ethylester；Ethyl phenyl(propan-2-yl)phosphinate；[ethoxy(propan-2-yl)phosphoryl]benzene
• CAS: 53716-14-6
• 化学式: C₁₁H₁₇O₂P
• 分子量: 212.229
• InChiKey: FJWLQMRRYCHTCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  isopropyl-phenyl-phosphinic acid ethyl ester 在 锂硼氢 作用下， 以 四氢呋喃 、 四氯乙烯 为溶剂， 反应 6.0h， 生成 isopropyl(phenyl)phosphinous acid-borane ethyl ester
  参考文献：
  名称：

  化学选择性还原O-烷基次膦酸酯和相关化合物的磷酰基键：显然不可能的转化

  摘要：

  报道了一种方法，用于O-烷基次膦酸酯，次膦酸酯硫代酸酯和某些膦酰胺代酸酯的磷酰基键裂解，以提供相应的P（III）硼烷加合物。

  DOI：

  10.1039/c5cc06389b
• 作为产物：
  描述：

  苯膦酰二氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 isopropyl-phenyl-phosphinic acid ethyl ester
  参考文献：
  名称：

  化学选择性还原O-烷基次膦酸酯和相关化合物的磷酰基键：显然不可能的转化

  摘要：

  报道了一种方法，用于O-烷基次膦酸酯，次膦酸酯硫代酸酯和某些膦酰胺代酸酯的磷酰基键裂解，以提供相应的P（III）硼烷加合物。

  DOI：

  10.1039/c5cc06389b

文献信息

• ESTERIFICATION OF PHOSPHONIC AND PHOSPHINIC ACID ANALOGUES OF GLUTAMIC AND ASPARTIC ACIDS WITH ETHYL ORTHOFORMATE-SCOPE AND LIMITATIONS OF THE METHOD
  作者：Ewa Żymańczyk-Duda、Barbara Lejczak、Paweł Kafarski

  DOI：10.1080/10426509608046348

  日期：1996.5.1

  Abstract Reaction of C-ethyl esters of phosphonic- and phosphinic acid analogues of glutamic and aspartic acids with ethyl orthoformate provides the mixtures of N-formylamino- and N-ethoxymethyleneimino-derivatives with nearly quantitative yields. Scope and limitations of this procedure were studied by means of GC/MS technique.

  摘要 谷氨酸和天冬氨酸的膦酸和次膦酸类似物的 C-乙酯与原甲酸乙酯的反应提供了 N-甲酰氨基和 N-乙氧基亚甲基亚氨基衍生物的混合物，收率几乎是定量的。该程序的范围和局限性通过 GC/MS 技术进行了研究。
• Phosphonate Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239921A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is a phosphonate (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包括式子I或其药学上可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备方法，其中在A基团上的R12或R13是磷酸酯（R32）。本文所述的抑制剂靶向因子D，在替代性补体途径的早期和关键点抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫性、炎症性和神经退行性疾病，以及缺血再灌注损伤和癌症有关。
• Phosphonate compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10000516B2

  公开（公告）日：2018-06-19

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

  提供了包含式 I 或其药学上可接受的盐或组合物（其中 A 基上的 R12 或 R13 是膦酸盐取代基 (R32)）的补体因子 D 抑制剂的化合物、使用方法和制造工艺。本文所述的抑制剂以因子 D 为靶点，抑制或调节补体级联。本文所述的因子 D 抑制剂可减少补体的过度活化。
• Phosphonate compounds for treatment of complement mediated disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10301336B2

  公开（公告）日：2019-05-28

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本发明提供了包含式 I 或其药学上可接受的盐或组合物（其中 A 基上的 R12 或 R13 是膦酸盐 (R32)）的补体因子 D 抑制剂的化合物、使用方法和制造工艺。本文所述的抑制剂以因子 D 为靶点，在替代补体途径的早期和关键点抑制或调节补体级联，并降低因子 D 调节经典和凝集素补体途径的能力。本文所述的因子 D 抑制剂能够减少补体的过度活化，而补体的过度活化与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• Alkylation of <i>H</i>-Phosphinate Esters under Basic Conditions
  作者：Isabelle Abrunhosa-Thomas、Claire E. Sellers、Jean-Luc Montchamp

  DOI：10.1021/jo062436o

  日期：2007.4.1

  An efficient and general procedure was developed for the direct alkylation of H-phosphinate esters with LHMDS at low temperature. The simplicity of the reaction allows the use of various H-phosphinate esters and takes place with a wide range of electrophiles. The approach can be employed to access some GABA analogues or precursors to GABA analogues. The isolated yields are moderate to good. This is the first report of an alkylation with a secondary iodide or a primary chloride.